72 related articles for article (PubMed ID: 9118459)
1. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract][Full Text] [Related]
2. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
4. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
6. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
7. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug.
Pendri A; Conover CD; Greenwald RB
Anticancer Drug Des; 1998 Jul; 13(5):387-95. PubMed ID: 9702205
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity of two novel taxanes.
Rose WC; Fairchild C; Lee FY
Cancer Chemother Pharmacol; 2001; 47(2):97-105. PubMed ID: 11269747
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
13. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of BMS-275183, an orally active taxane.
Rose WC; Long BH; Fairchild CR; Lee FY; Kadow JF
Clin Cancer Res; 2001 Jul; 7(7):2016-21. PubMed ID: 11448919
[TBL] [Abstract][Full Text] [Related]
15. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
18. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
Ojima I; Slater JC; Michaud E; Kuduk SD; Bounaud PY; Vrignaud P; Bissery MC; Veith JM; Pera P; Bernacki RJ
J Med Chem; 1996 Sep; 39(20):3889-96. PubMed ID: 8831755
[TBL] [Abstract][Full Text] [Related]
20. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]